Abstract
A small proportion of lung adenocarcinomas harbour ROS1 gene arrangements and are sensitive to ROS1 tyrosine kinase inhibitors. In Australia, ROS1 immunohistochemistry (IHC) is used to screen for ROS1 rearrangements in lung adenocarcinomas followed by confirmatory molecular testing such as fluorescence in situ hybridisation (FISH), if other genetic driver alterations are negative. The optimal threshold for determining ROS1 IHC positivity is not well defined, and this study aims to determine the best threshold for ROS1 IHC screening to identify all ROS1 rearranged lung adenocarcinomas.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
